181 related articles for article (PubMed ID: 29056538)
1. The role of RAS mutations in MLL-rearranged leukaemia: A path to intervention?
Mansur MB; Ford AM; Emerenciano M
Biochim Biophys Acta Rev Cancer; 2017 Dec; 1868(2):521-526. PubMed ID: 29056538
[TBL] [Abstract][Full Text] [Related]
2. MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.
Kerstjens M; Driessen EM; Willekes M; Pinhanços SS; Schneider P; Pieters R; Stam RW
Oncotarget; 2017 Feb; 8(9):14835-14846. PubMed ID: 27588400
[TBL] [Abstract][Full Text] [Related]
3. Subclonality and prenatal origin of RAS mutations in KMT2A (MLL)-rearranged infant acute lymphoblastic leukaemia.
Emerenciano M; Barbosa Tda C; de Almeida Lopes B; Meyer C; Marschalek R; Pombo-de-Oliveira MS
Br J Haematol; 2015 Jul; 170(2):268-71. PubMed ID: 25613690
[No Abstract] [Full Text] [Related]
4. The role of constitutive activation of FMS-related tyrosine kinase-3 and
Fedders H; Alsadeq A; Schmäh J; Vogiatzi F; Zimmermann M; Möricke A; Lenk L; Stadt UZ; Horstmann MA; Pieters R; Schrappe M; Stanulla M; Cario G; Schewe DM
Haematologica; 2017 Nov; 102(11):e438-e442. PubMed ID: 28838992
[No Abstract] [Full Text] [Related]
5. Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants.
Driessen EM; van Roon EH; Spijkers-Hagelstein JA; Schneider P; de Lorenzo P; Valsecchi MG; Pieters R; Stam RW
Haematologica; 2013 Jun; 98(6):937-44. PubMed ID: 23403319
[TBL] [Abstract][Full Text] [Related]
6. Relapsed infant MLL-rearranged acute lymphoblastic leukemia with additional genetic alterations.
Ishida H; Kanamitsu K; Washio K; Muraoka M; Sakakibara K; Matsubara T; Kanzaki H; Shimada A
Pediatr Blood Cancer; 2016 Nov; 63(11):2059-60. PubMed ID: 27322816
[No Abstract] [Full Text] [Related]
7. The potential of clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia.
Stumpel DJ; Schneider P; Pieters R; Stam RW
Eur J Cancer; 2015 Sep; 51(14):2008-21. PubMed ID: 26188848
[TBL] [Abstract][Full Text] [Related]
8. Trametinib inhibits
Kerstjens M; Pinhancos SS; Castro PG; Schneider P; Wander P; Pieters R; Stam RW
Haematologica; 2018 Apr; 103(4):e147-e150. PubMed ID: 29419436
[No Abstract] [Full Text] [Related]
9. MLL-Rearranged Acute Lymphoblastic Leukemia.
El Chaer F; Keng M; Ballen KK
Curr Hematol Malig Rep; 2020 Apr; 15(2):83-89. PubMed ID: 32350732
[TBL] [Abstract][Full Text] [Related]
10. MLL-rearranged infant leukaemia: A 'thorn in the side' of a remarkable success story.
Rice S; Roy A
Biochim Biophys Acta Gene Regul Mech; 2020 Aug; 1863(8):194564. PubMed ID: 32376390
[TBL] [Abstract][Full Text] [Related]
11. The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias.
Andersson AK; Ma J; Wang J; Chen X; Gedman AL; Dang J; Nakitandwe J; Holmfeldt L; Parker M; Easton J; Huether R; Kriwacki R; Rusch M; Wu G; Li Y; Mulder H; Raimondi S; Pounds S; Kang G; Shi L; Becksfort J; Gupta P; Payne-Turner D; Vadodaria B; Boggs K; Yergeau D; Manne J; Song G; Edmonson M; Nagahawatte P; Wei L; Cheng C; Pei D; Sutton R; Venn NC; Chetcuti A; Rush A; Catchpoole D; Heldrup J; Fioretos T; Lu C; Ding L; Pui CH; Shurtleff S; Mullighan CG; Mardis ER; Wilson RK; Gruber TA; Zhang J; Downing JR;
Nat Genet; 2015 Apr; 47(4):330-7. PubMed ID: 25730765
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of MEK and ATR is effective in a B-cell acute lymphoblastic leukemia model driven by
Chu SH; Song EJ; Chabon JR; Minehart J; Matovina CN; Makofske JL; Frank ES; Ross K; Koche RP; Feng Z; Xu H; Krivtsov A; Nussenzweig A; Armstrong SA
Blood Adv; 2018 Oct; 2(19):2478-2490. PubMed ID: 30266823
[TBL] [Abstract][Full Text] [Related]
13. Relatively favorable prognosis for MLL-rearranged childhood acute leukemia with reciprocal translocations.
Yang L; Ding L; Liang J; Chen J; Tang Y; Xue H; Gu L; Shen S; Li B; Chen J
Pediatr Blood Cancer; 2018 Oct; 65(10):e27266. PubMed ID: 29943896
[TBL] [Abstract][Full Text] [Related]
14. The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis.
Garrido Castro P; van Roon EHJ; Pinhanços SS; Trentin L; Schneider P; Kerstjens M; Te Kronnie G; Heidenreich O; Pieters R; Stam RW
Leukemia; 2018 Feb; 32(2):323-331. PubMed ID: 28690313
[TBL] [Abstract][Full Text] [Related]
15. Bilateral ovarian B-lineage lymphoblastic lymphoma with MLL gene rearrangement: a novel case in infancy.
Larish AM; Dolan M; Casey T; Perkins JL
J Pediatr Hematol Oncol; 2015 May; 37(4):e215-7. PubMed ID: 25493458
[TBL] [Abstract][Full Text] [Related]
16. Azacitidine successfully maintained the second remission in an infant with KMT2A-rearranged acute lymphoblastic leukemia who relapsed after unrelated cord blood transplantation.
Chijimatsu I; Imanaka Y; Tomizawa D; Eguchi M; Nishimura S; Karakawa S; Miki M; Hamamoto K; Fujita N
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28675638
[TBL] [Abstract][Full Text] [Related]
17. Targeting PRMT1-mediated FLT3 methylation disrupts maintenance of MLL-rearranged acute lymphoblastic leukemia.
Zhu Y; He X; Lin YC; Dong H; Zhang L; Chen X; Wang Z; Shen Y; Li M; Wang H; Sun J; Nguyen LX; Zhang H; Jiang W; Yang Y; Chen J; Müschen M; Chen CW; Konopleva MY; Sun W; Jin J; Carlesso N; Marcucci G; Luo Y; Li L
Blood; 2019 Oct; 134(15):1257-1268. PubMed ID: 31395602
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of high-level FLT3 expression in MLL-rearranged infant acute lymphoblastic leukemia.
Stam RW; Schneider P; de Lorenzo P; Valsecchi MG; den Boer ML; Pieters R
Blood; 2007 Oct; 110(7):2774-5. PubMed ID: 17881645
[No Abstract] [Full Text] [Related]
19. Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner.
Brown P; Levis M; McIntyre E; Griesemer M; Small D
Leukemia; 2006 Aug; 20(8):1368-76. PubMed ID: 16761017
[TBL] [Abstract][Full Text] [Related]
20. Src kinase-induced phosphorylation of annexin A2 mediates glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia.
Spijkers-Hagelstein JA; Mimoso Pinhanços S; Schneider P; Pieters R; Stam RW
Leukemia; 2013 Apr; 27(5):1063-71. PubMed ID: 23334362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
